X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
P18-BE3CRC is a drug candidate developed using the Phageria platform technology for bacteriophage-based drugs. It is being evaluated in preclinical trials for the treatment of colorectal cancer.
Lead Product(s): P18-BE3CRC
Therapeutic Area: Oncology Product Name: P18-BE3CRC
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license LSVT-1701 (tonabacase) for further clinical development and commercialization.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: LSVT-1701
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: $CHECK CHECK Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 31, 2023
Details:
Under the agreement, Basilea will investigate SAL200 (tonabacase), a potential first-in-class clinical-stage antibacterial of the endolysin class, against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: SAL200
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 31, 2023
Details:
Under the agreement, iNtRON grants Basilea exclusive right for preclinical evaluation of the antibacterial bio-drug N-Rephasin SAL200 (tonabacase), a novel endolysin-based anti-staphylococcal drug formulated for injection.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: N-Rephasin SAL200
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2023
Details:
The agreement aims to develop bacteriophages targeting strains causing urinary tract infections for combating Uropathogenic Escherichia coli (UPEC) infections.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: U.S. Army DEVCOM
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 03, 2023
Details:
CDL200 is a novel endolysin-based anti- Clostridioides difficile causes an infection of colon, showed potent and rapid activity against 100% clinical isolates from multi-nation and has no disturbance of normal flora in human's gut.
Lead Product(s): CDL200
Therapeutic Area: Infections and Infectious Diseases Product Name: CDL200
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
